from the CAA website... (Public domain, but not necessarily easily navigable)
see
Medication used for musculoskeletal conditions | Medical | Personal Licences and Training
Cytokine modulators
Etanercept and adalimumab inhibit the activity of tumour necrosis factor alpha (TNF-α). These are the only medicines in this group that are acceptable for aeromedical certification at present. They are licensed for use in moderate to severe rheumatoid arthritis, psoriatic arthritis and ankylosing spondylitis when response to other disease modifying drugs has been inadequate. Flying can resumed (with an OML for Class 1 holders) provided symptoms are satisfactorily controlled, there are no significant musculoskeletal impairments and there are no significant side effects four weeks after initiation of treatment.